Merit Medical Q1 2026 Revenue Reclassification Strategy Analysis
This analysis explores Merit Medical's strategic shift in revenue reporting, focusing on its implications for Q1 2026 performance and investor understanding.
Read postDetailed company information
Merit Medical Systems, Inc. (MMSI) is engaged in the design, development, manufacturing, and worldwide commercialization of disposable medical products. These devices are crucial for a broad spectrum of diagnostic, therapeutic, and interventional procedures, primarily within the fields of cardiology, radiology, oncology, critical care, and endoscopy. The company operates through two main divisions: Cardiovascular and Endoscopy. Its extensive product portfolio includes advanced solutions for diagnosing and treating conditions in peripheral vessels and organs, as well as a comprehensive suite of cardiac intervention products. The latter encompasses tools for vascular access, angiography, electrophysiology, cardiac rhythm management, fluid and hemodynamic monitoring, hemostasis, and various interventional therapies for heart-related ailments. Additionally, MMSI provides customized procedural solutions, offering critical care items, disinfection protection systems, specialized syringes, manifold kits, and tailored trays and packs. Their offerings further extend to coated tubes and wires, alongside sophisticated sensor components for microelectromechanical systems (MEMS). The company also features pulmonary products, such as laser-cut tracheobronchial stents with their accompanying over-the-wire and direct visualization delivery systems, and dilation balloons used for endoscopic stricture dilation. Gastroenterology products, as well as essential kits and accessories for endoscopy and bronchoscopy procedures, complete their diverse catalog. Merit Medical Systems sells its products to a wide client base, including hospitals and healthcare professionals (physicians, technicians, and nurses) working in alternative care settings. Distribution channels include a direct sales force, authorized distributors, original equipment manufacturer (OEM) partnerships, and custom procedure tray manufacturers, reaching customers throughout the United States and internationally. Founded in 1987, Merit Medical Systems, Inc. has its corporate headquarters situated in South Jordan, Utah.
Last Updated: Sep 2026
Earnings Transcript for 2026 - Q2Released: Jul 30, 2026
Earnings Transcript for 2026 - Q1Released: Apr 30, 2026
Earnings Transcript for 2025 - Q4Released: Feb 25, 2026
Earnings Transcript for 2025 - Q3Released: Oct 30, 2025
Earnings Transcript for 2025 - Q2Released: Jul 31, 2025
Earnings Transcript for 2025 - Q1Released: Apr 25, 2025
Earnings Transcript for 2024 - Q4Released: Feb 25, 2025
Earnings Transcript for 2024 - Q3Released: Oct 30, 2024
Earnings Transcript for 2024 - Q2Released: Aug 03, 2024
Earnings Transcript for 2024 - Q1Released: Apr 30, 2024
Earnings Transcript for 2023 - Q4Released: Feb 28, 2024
Earnings Transcript for 2023 - Q3Released: Oct 26, 2023
Earnings Transcript for 2023 - Q2Released: Jul 26, 2023
Earnings Transcript for 2023 - Q1Released: Apr 26, 2023
Earnings Transcript for 2022 - Q4Released: Feb 22, 2023
Earnings Transcript for 2022 - Q3Released: Oct 26, 2022
Earnings Transcript for 2022 - Q2Released: Jul 28, 2022
Earnings Transcript for 2022 - Q1Released: Apr 27, 2022
Earnings Transcript for 2021 - Q4Released: Feb 26, 2022
Earnings Transcript for 2021 - Q3Released: Oct 28, 2021
Earnings Transcript for 2021 - Q2Released: Jul 31, 2021
Earnings Transcript for 2021 - Q1Released: Apr 30, 2021
Earnings Transcript for 2020 - Q4Released: Feb 24, 2021
Earnings Transcript for 2020 - Q3Released: Oct 28, 2020
ANGO AngioDynamics, Inc.
ICUI ICU Medical, Inc.
HAE Haemonetics Corporation
NVST Envista Holdings Corp
XRAY DENTSPLY SIRONA Inc.
ATR AptarGroup, Inc.
TFX Teleflex Incorporated
COO The Cooper Companies, Inc.
WST West Pharmaceutical Services, Inc.
RMD ResMed Inc.
BSX Boston Scientific Corporation
VIVO VivoPower PLC
This analysis explores Merit Medical's strategic shift in revenue reporting, focusing on its implications for Q1 2026 performance and investor understanding.
Read postMerit Medical projects $7 million in U.S. revenues for its Rhapsody product in 2026, based on unit-volume and ASP assumptions inferred from market data and management commentary. This guidance reflects modest market penetration primarily in the non-hospital setting.
Read post